Dechra Pharmaceuticals Manufacturing
Dechra Pharmaceuticals Manufacturing is the manufacturing business of Dechra Pharmaceuticals PLC, operating from two European sites at Skipton, UK, Bladel, NL and also Melbourne USA.
Dechra Pharmaceuticals Manufacturing is the manufacturing business of Dechra Pharmaceuticals PLC, operating from two European sites at Skipton, UK, Bladel, NL and also Melbourne USA.
Dechra Pharmaceuticals Manufacturing provides a comprehensive range of contract pharmaceutical services.
Our mission is to provide an excellent service, developing and supplying quality products to our customers worldwide.
Dechra is a complete service provider, offering product development through manufacturing and packing to QP release, supported by highly qualified staff, trained to the highest standard.
Ongoing investment in the factory at Skipton, has created a, well equipped, MHRA and FDA approved cGMP facility that produces a diverse range of dosage forms and wide scale of volumes and batch sizes, including scale-up and commercial batch production. The site comprises multiple manufacturing and packing suites with QC, validation and development laboratories. It also has a 160 pallet CD store.
Dechra's cGMP facility at Bladel, Netherlands is IGZ approved to manufacture, import and pack pharmaceuticals for veterinary use, including controlled drugs.
The Melbourne facility produces tablets and chews for the US veterinary market.
All in all we are, Your Complete Pharmaceutical Service Provider.
Contact:
Dechra Pharmaceuticals Manufacturing
Email: manufacturing.enquiries@dechra.com
Website: www.dechramanufacturing.com
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
The Role of Forced Degradation in Method Development, Manufacturability, and CMC Strategy
April 28th 2025Forced degradation studies are critical in biologics development, particularly for monoclonal antibodies (mAbs). These studies simulate long-term environmental stressors to uncover degradation pathways and ensure the stability of critical quality attributes (CQAs), aiding in robust chemistry, manufacturing, and controls (CMC) strategies and regulatory compliance.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
